Aaron C Logan

TL;DR: Ibrutinib resulted in clinically meaningful responses with acceptable safety in patients with ≥1 prior treatments for cGV HD, and was approved in the United States for treatment of adult patients with cGVHD after failure of 1 or more lines of systemic therapy.

TL;DR: Dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML are illustrated.

TL;DR: The pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study evaluating the efficacy and safety of the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies.

TL;DR: Limited available evidence for 5 off-label, in-hospital indications suggests no mortality reduction with rFVIIa use and, for some indications, it increases thromboembolism.

TL;DR: IGH-HTS using consensus primers will broaden the availability of MRD quantification in CLL and other B cell malignancies, and this approach has potential for quantitative evaluation of immune diversification following transplant and nontransplant therapies.